Core Viewpoint - Heng Rui Medicine (01276) has seen a stock price increase of nearly 3%, currently trading at 72.35 HKD, following the announcement of receiving clinical trial approval for its drug, Fumaric Acid Tegeline Injection, from the National Medical Products Administration [1] Group 1: Company Developments - On November 17, Heng Rui Medicine announced that it received the clinical trial approval notice for Fumaric Acid Tegeline Injection from the National Medical Products Administration [1] - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist, set to be approved for domestic market launch in January 2024, marking it as China's first independently developed Class 1 opioid analgesic innovation drug [1] - The company has invested approximately 200 million RMB in the research and development of Fumaric Acid Tegeline Injection to date [1] Group 2: Market Context - A similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, was approved for sale in the United States in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023, although no sales data has been reported yet [1]

Core Viewpoint - Heng Rui Medicine (600276) has seen a nearly 3% increase in stock price, currently trading at 72.35 HKD, following the announcement of clinical trial approval for its drug, Fumaric Acid Tegeline Injection, by the National Medical Products Administration of China [1] Group 1: Company Developments - On November 17, Heng Rui Medicine announced that it received the clinical trial approval notice for Fumaric Acid Tegeline Injection from the National Medical Products Administration [1] - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist, set to be approved for domestic market launch in January 2024, marking it as China's first independently developed Class 1 opioid analgesic innovation drug [1] - The company has invested approximately 200 million RMB in the research and development of Fumaric Acid Tegeline Injection to date [1] Group 2: Market Context - The drug has a comparable product, Oliceridine (brand name: Olinvyk), developed by Trevena, which was approved for sale in the United States in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023, although no sales data has been reported yet [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Fumaric Acid Tegeline Injection, marking a significant step in the development of China's first independently developed Class 1 opioid analgesic [1] Group 1: Product Development - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist [1] - The product is expected to be launched in China in January 2024 [1] - The company has invested approximately 200 million yuan in the research and development of this project [1] Group 2: Market Context - Oliceridine, a similar product developed by Trevena, was approved for sale in the United States in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023 [1] - No sales data for Oliceridine in China has been reported as of now [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Fumaric Acid Tegilide Injection, marking a significant step in the development of China's first independently developed class 1 opioid analgesic [1] Company Summary - Heng Rui Medicine's Fumaric Acid Tegilide Injection is a μ-opioid receptor (MOR) biased small molecule agonist, expected to be approved for domestic market launch in January 2024 [1] - The company has invested approximately 199.99 million yuan in the research and development of Fumaric Acid Tegilide Injection to date [1] Industry Summary - Fumaric Acid Tegilide Injection is positioned as a novel opioid analgesic in China, with a similar product, Oliceridine (brand name: Olinvyk), developed by Trevena, already approved in the U.S. in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023, although sales data is currently unavailable [1]